Stockholm: Europe is losing ground against some of its most dangerous bacteria, according to new surveillance data showing a sharp rise in bloodstream infections that resist the antibiotics doctors rely on most. The figures, drawn from the European Antimicrobial Resistance Surveillance Network covering thirty countries, paint a picture of a slow-motion crisis that public health officials have warned about for years and now watch unfolding in real time.
The starkest number concerns Klebsiella pneumoniae, a gut bacterium that can turn deadly when it enters the blood. Infections resistant to carbapenems, the powerful antibiotics held in reserve for the toughest cases, rose by sixty-one percent between 2019 and 2024. When carbapenems fail, clinicians are pushed toward older, more toxic drugs or combinations of last resort, and for some patients no reliable option remains. A more common threat, E. coli resistant to third-generation cephalosporins, climbed nearly six percent over the same period, a smaller jump but one affecting far larger numbers of people.
Those trajectories collide with political promises. The European Union set itself targets for 2030 to cut the incidence of both pathogens, by five percent and ten percent respectively, as part of a broader pledge to bend the curve on resistance. On current trends the surveillance agency judges those goals unlikely to be met. The gap between ambition and reality matters because antimicrobial resistance already claims an estimated thirty-five thousand lives a year across the union and its neighbours, a toll comparable to influenza, road accidents and other hazards that command far more public attention.
The drivers are well understood, which is part of what makes the failure so frustrating. Antibiotics are still prescribed too readily for ailments they cannot treat, dispensed without prescription in some markets and used heavily in animal agriculture. Each unnecessary course gives bacteria another chance to evolve defences. Hospitals, where the sickest and most vulnerable patients are concentrated, act as crucibles for resistant strains that then spread through wards on hands, instruments and shared surfaces. Infection control, the unglamorous work of hygiene and isolation, remains uneven across the continent.
Demography sharpens the danger. As Europe’s population ages, more people undergo the surgeries, cancer treatments and intensive-care stays that depend on antibiotics working in the background. A hip replacement or a course of chemotherapy carries acceptable risk only because doctors can fend off the infections such procedures invite. Erode that protection and the foundations of modern medicine begin to crack. Modelling that layers rising resistance onto an older population suggests the future burden could climb well beyond today’s figures unless prescribing and prevention change course.
The policy toolkit exists but works slowly. Stewardship programmes that police prescribing, surveillance that catches outbreaks early and incentives to develop new antibiotics all feature in the union’s strategy. The trouble is that the pharmaceutical pipeline has nearly run dry, because antibiotics are unprofitable by design: a successful new drug must be used as little as possible to preserve its power, the opposite of the blockbuster model that funds research. Various reward schemes have been floated to fix that broken market, but none has yet delivered the steady stream of new compounds the situation demands.
Public health officials frame the latest data as a call to act before the window narrows further. Resistance, once entrenched in a population of bacteria, is fiendishly hard to reverse, which means the cheapest interventions are the ones taken now. Whether Europe’s health systems, stretched by staffing shortages and competing priorities, can summon that urgency is the uncomfortable question the figures leave behind.
